As COPD is inherently a heterogeneous pulmonary condition persisting throughout the disease progression, Professor Klaus F. Rabe from the LungClinic Grosshansdorf, University of Kiel in Germany, stressed that 20 percent to 40 percent of COPD patients are primarily driven by type 2 inflammation pathways, and targeted therapies hold promise for meeting individual treatment needs.

Professor Wisia Wedzicha from Imperial College London stressed that clinical identification of inflammatory endotypes, particularly type 2 inflammation, is one of the prerequisites for precision COPD treatment.

Based on the results of inflammatory pathway studies, Professor Chen Yan from the Second Xiangya Hospital of Central South University underscored the vital role of biologics that target type 2 inflammation in managing chronic airway diseases, adding that since 2010, the exploration of biologics that target type 2 inflammation has been ongoing.

Professor Surya P. Bhatt from the University of Alabama at Birmingham introduced biologics targeting key drivers in type 2 inflammation pathways and shared efficacy study results, expressing high expectations for biologics currently under investigation.

During the panel discussions, experts engaged in in-depth discussions on diagnostic and treatment strategies for COPD.

Professor Sun Dejun from Inner Mongolia People's Hospital remarked in his closing summary that the summit brought together top experts from around the world to deeply discuss the latest advancements in respiratory diseases, particularly targeting therapies. The insights gained offer valuable guidance for clinical practice, with the hope of benefiting more patients.